The Vance Paradox: Conservative Politics, Biotech Billions

Published on 22 July 2025 at 07:54

The public identity of J.D. Vance is firmly rooted in national conservatism, a political philosophy he has embraced and actively promoted. He identifies as a member of the postliberal right and has been influenced by Catholic social teaching, often aligning himself with paleoconservative figures such as Pat Buchanan. Vance's public pronouncements consistently advocate for a staunchly pro-life stance, a position he has articulated through calls for national abortion bans and controversial views on exceptions for rape and incest. He has also championed "pro-family" and natalist policies, emphasizing the critical need to boost birth rates in the United States and support families. Yet, beneath this carefully constructed public persona lies a complex web of private financial interests, particularly within the burgeoning biotechnology sector, which invites rigorous scrutiny. These investments, alongside his profound and influential ties to billionaire venture capitalist Peter Thiel and his stake in the alternative media platform Rumble, present an apparent contradiction with his stated principles, prompting a deeper examination of how his capitalist pursuits intersect with his conservative convictions.

 

Vance's self-description as a "national conservative" and "postliberal right" member is not merely a descriptive label but a strategic positioning. His adoption of Catholic social teaching provides a moral framework for his pro-life and natalist views, which he has consistently articulated. This consistent articulation serves to solidify his base and appeal to a specific segment of the electorate. The consequence of this carefully cultivated political brand is that any deviation or perceived inconsistency in his financial dealings could undermine its authenticity, leading to questions about his sincerity or potential conflicts of interest. This sets the stage for the investigative core of this analysis.

The Public Persona: Pillars of a Socially Conservative Platform

J.D. Vance's political identity is defined by his unwavering commitment to socially conservative principles, particularly on issues related to life and family. He has consistently advocated for stringent anti-abortion measures, going so far as to call for a national abortion ban, a position he affirmed by stating he "certainly would like abortion to be illegal nationally". His rhetoric has been particularly stark, equating abortion to slavery, asserting that "two wrongs don't make a right" and that abortion has a "morally distorting effect on the entire society". While he has recently softened his stance on exceptions for rape and incest, his earlier comments dismissed such circumstances as "inconvenient," prioritizing the life of the unborn child above all else. This hardline position is further underscored by his opposition to Ohio's constitutional amendment guaranteeing abortion rights.

 

Beyond abortion, Vance is a vocal proponent of "pro-family" and natalist policies, frequently emphasizing the need to increase birth rates in the United States. He has expressed interest in expanding the child tax credit and even proposed forgivable loans for married couples with at least three children, aiming to make it "easier for moms to afford to have babies" and for young families to afford homes. His views on childlessness, linking it to sociopathy, further underscore his natalist convictions.

 

His stance on in vitro fertilization (IVF) presents a more complex picture, one that appears to shift over time. While he has publicly expressed support for fertility treatments and signed a statement with other Senate Republicans pledging "continued nationwide access to IVF," his voting record reveals a different narrative. Vance opposed a Democratic-led bill in June that would have established a nationwide right to IVF, and he did not vote on a similar measure in September. He has also voiced concerns about religious liberty related to IVF, suggesting Christian hospitals should not be required to provide such services. This position is particularly pertinent given the Alabama Supreme Court's ruling that frozen embryos are children, a decision that has led to the pausing of IVF services in the state and raised concerns about potential criminal charges for embryo mishandling. The Catholic Church, which Vance cites as an influence, views IVF as morally problematic because it separates procreation from the marital act and often involves the destruction of embryos.

 

Vance's public support for IVF appears to be a political necessity, given its popularity among conservatives, as well as the "pro-family" image he cultivates. However, his voting record against federal IVF protections and his alignment with Project 2025's stance on defunding stem cell research reveal a more profound ideological commitment that, when fully realized, would logically restrict or complicate IVF access. The Alabama ruling serves as a concrete illustration of the direct conflict between a "pro-life" interpretation of personhood, extending to embryos, and the practice of IVF. His Catholic influence further highlights this internal tension, as Catholic teaching is generally opposed to IVF. This suggests that Vance is attempting to navigate a politically sensitive issue by offering rhetorical support while maintaining policy positions that are fundamentally at odds with widespread access to IVF, creating a significant inconsistency between his words and actions.

 

Vance's alignment with broader conservative movements is also evident in his ties to Project 2025, a Heritage Foundation initiative aimed at dismantling perceived government bureaucracy and implementing a range of conservative policies. Notably, Project 2025 proposes making the National Institutes of Health (NIH) less independent and defunding its stem cell research, a policy that directly impacts the scientific landscape surrounding biotechnology.

The Private Portfolio: Biotech Ventures and Ethical Entanglements

J.D. Vance's career trajectory includes a significant period as a venture capitalist, a background that continues to shape his financial interests while in public office. His financial disclosures reveal investments in several biotech firms, raising questions about the intersection of his wealth and his public policy positions.

 

Among his notable holdings are investments in Kriya Therapeutics, AmplifyBio, and Beren Therapeutics. Kriya Therapeutics is a biopharmaceutical gene therapy company focused on developing "life-changing gene therapies" for chronic diseases across ophthalmology, metabolic disease, and neurology. Their approach involves advanced engineering principles and computational tools to optimize the design, development, and manufacturing of gene therapies, aiming for "one-time gene therapies" that are both transformative and accessible. AmplifyBio, on the other hand, operated as a preclinical Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) for advanced therapeutics, including cell and gene therapies, as well as mRNA. While AmplifyBio has since filed for Chapter 11 bankruptcy and wound down operations as of May 2025, Vance's prior investment in it is relevant to the period under scrutiny. Beren Therapeutics, founded in 2020, remains largely in "stealth mode," though patent activity suggests work on compositions and methods for treating sickle cell disease and modular manufacturing for pharmaceuticals. Vance's investment in Beren Therapeutics was between $15,001 and $50,000.

 

The critical question in this investigation centers on the connection between these companies' operations and embryonic stem cell research. Embryonic stem cells (ESCs) are pluripotent cells derived from 3 to 5-day-old embryos, capable of developing into any cell type in the body, making them highly valuable for regenerative medicine. However, their use is highly controversial due to the destruction of embryos involved in their derivation. Federal funding for ESC research has been limited since 1995 by the Dickey-Wicker Amendment, which prohibits federal funds for research in which human embryos are created or destroyed, though non-federal funding is permitted.

 

AmplifyBio, when questioned about its use of stem cell lines, stated that it does not directly use them in its testing but also does not require the companies it works with to disclose whether such cells were used in development. This creates a significant ethical gray area. While Kriya Therapeutics and Beren Therapeutics do not explicitly mention embryonic stem cells in their public descriptions, their focus on gene therapy and advanced therapeutics places them within a broader biotechnology landscape where various types of stem cells, including adult stem cells and induced pluripotent stem cells (iPSCs), are utilized. The distinction is crucial: adult stem cells and iPSCs do not carry the same ethical baggage as ESCs because they do not involve the destruction of embryos. However, the field of "advanced therapies" is broad, and the moral lines can become blurred when indirect associations or supply chains are taken into account.

 

Vance's pro-life stance is absolute, viewing abortion as comparable to slavery and opposing exceptions. This position logically extends to the ethical concerns surrounding embryonic stem cell research, which involves the destruction of embryos. His investments in biotech firms like Kriya Therapeutics and AmplifyBio are in a field that broadly encompasses regenerative medicine and gene therapy. While Kriya and Beren do not explicitly mention ESCs, AmplifyBio's admission that it does not directly use ESCs but also does not require clients to disclose whether they were used in development is a critical point. This means Vance's investments, while not directly funding embryo destruction, are in companies that operate within an ecosystem that may, at some level, benefit from or be connected to research that utilizes embryonic stem cells. This creates an "indirect ethical entanglement," where his financial interests are not entirely insulated from the ethical concerns he champions politically, highlighting a complex and perhaps unavoidable tension in modern biotech investment.

 

Table 1: J.D. Vance's Key Biotech Investments

Company Name Vance's Reported Investment Range Primary Business Focus Direct Use of Embryonic Stem Cells
Kriya Therapeutics $50,001-$100,000   Gene therapy for ophthalmology, metabolic disease, neurology   No explicit mention of ESCs in company descriptions. Focus on gene therapy using AAV vectors.  
AmplifyBio $50,001-$100,000 and $1,001-$15,000   Preclinical CRO and CDMO for cell and gene therapies, mRNA.   Stated they do not directly use stem cell lines but do not require clients to disclose
Beren Therapeutics $15,001-$50,000   Biotechnology company in "stealth mode," patents suggest work on sickle cell disease and modular manufacturing.   No explicit mention of ESCs in company descriptions.  
Company Name Vance's Reported Investment Range Primary Business Focus Direct Use of Embryonic Stem Cells

This table provides concrete data on Vance's specific biotech investments, detailing the companies, investment ranges, and their primary business focuses. Crucially, it directly addresses the question of embryonic stem cell use, highlighting AmplifyBio's nuanced position. This factual foundation allows for a clear understanding of the basis for the perceived inconsistencies and the nature of the "indirect ethical entanglement" within his portfolio.

The Thiel Nexus: Ideology, Innovation, and Influence

The relationship between J.D. Vance and billionaire investor Peter Thiel is not merely transactional but profoundly influential, spanning professional mentorship, shared ventures, and ideological alignment. Vance's career in venture capital began at Thiel's Silicon Valley firm, Mithril Capital, where he served as a principal between 2016 and 2017. Following this, Vance co-founded his own venture capital firm, Narya Capital, in Cincinnati in 2019, with significant financial backing from Thiel, Eric Schmidt, and Marc Andreessen. This long-standing connection positions Thiel not just as an investor, but as a key figure in Vance's professional and financial ecosystem.

 

Peter Thiel's investment philosophy is characterized by a contrarian approach, seeking out "smart people solving difficult problems" and investing in startups that offer products or services "an order of magnitude better than the competition". His vision extends beyond mere profit, deeply engaging with themes of "life extension" and "immortality," famously calling death a "bug in the program" that can and must be fixed. He has invested millions in organizations like the Methuselah Foundation and SENS, which aim to "unlock longevity," as well as companies such as Unity Biotechnology, which targets cellular aging.

 

Crucially, Thiel has also invested heavily in biotech companies focusing on "stem cells," most notably Stemcentrx, a private firm developing cancer drugs. It is vital to distinguish this: Stemcentrx's focus is on cancer stem cells, which are believed to be the origin of various common cancers, and their research aims to identify and destroy these specific cells. This is distinct from embryonic stem cells, which are derived from early-stage embryos and carry the ethical controversy of embryo destruction. While both involve "stem cells," the biological source and ethical implications differ significantly. Thiel's interest in Stemcentrx aligns with his broader goal of combating human limitation and disease through advanced biotechnology.

 

Thiel's ideological currents, often described as techno-libertarianism or transhumanism, advocate for technological mastery over human biology and societal structures. He envisions "technocratic leadership" and "root-access elites" who lead by competence rather than popularity, and has even co-funded initiatives like The Seasteading Institute, which explores the concept of floating communities free from national law. This worldview, which seeks to "refactor" old systems and overcome biological limitations, presents a philosophical tension with traditional social conservatism, which often emphasizes natural order, traditional values, and the sanctity of life from conception. Vance's deep financial and professional ties to Thiel, whose vision is precisely about pushing these technological and biological boundaries, suggest a potential ideological influence or at least a tolerance for a broader biotechnological enterprise that extends beyond traditional ethical boundaries typically associated with his stated pro-life positions.

 

Vance's close association with Peter Thiel is not just a financial relationship but a conduit for ideological influence. Thiel's explicit pursuit of "life extension" and "immortality," viewing death as a "bug," represents a form of transhumanism, the belief that humanity can and should be improved through technology. While Thiel's investments in "stem cell" companies, such as Stemcentrx, specifically target cancer stem cells rather than embryonic ones, the broader implication is that Vance is financially tied to a network and a philosophy that champions radical biotechnological intervention in human life. This creates a subtle but profound inconsistency with Vance's socially conservative platform, which is rooted in traditional values, Catholic social teaching, and the sanctity of life. His pro-life stance emphasizes the natural order and the protection of life from conception, while Thiel's vision seeks to transcend natural biological limitations. Vance's financial participation in ventures aligned with Thiel's vision suggests either a compartmentalization of his beliefs or an implicit acceptance of a technological trajectory that could, in its extreme forms, challenge the very "natural order" he publicly upholds. This is a deeper ideological tension, not just a financial one.

 

Table 2: Peter Thiel's Relevant Biotech/Longevity Investments

Company Name Investment Focus Relevance to Embryonic Stem Cells
Methuselah Foundation / SENS Research Foundation Longevity research, "unlock longevity," anti-aging   Focus on cellular aging and extending lifespan, not directly involving embryonic stem cell destruction.
Unity Biotechnology Targets cellular aging   Focus on cellular aging, not directly involving embryonic stem cell destruction.
Stemcentrx Developing cancer drugs by targeting cancer stem cells   Focus on cancer stem cells, which are distinct from embryonic stem cells and do not involve embryo destruction.  
Company Name Investment Focus Relevance to Embryonic Stem Cells

This table clarifies Thiel's specific investments in the biotech and longevity sectors, demonstrating his focus on anti-aging and cancer stem cells. It is particularly valuable in differentiating these investments from those involving embryonic stem cells, thus providing critical context for understanding the nature of Thiel's influence and the philosophical landscape Vance navigates.

Rumble's Echo Chamber: Media, Politics, and Profit

J.D. Vance's investment portfolio extends beyond biotechnology into the realm of digital media, notably including a significant financial stake in Rumble, a Canadian online video platform. Vance held two tranches of Rumble shares in 2022, valued between $100,001 and $250,000, and another between $15,001 and $50,000. This investment aligns strategically with Vance's public criticisms of "Big Tech" and his broader advocacy for "digital liberty" and a "de-woke-ification program".

 

Rumble's business model is explicitly positioned as an anti-Big Tech alternative, appealing to a conservative audience with its transparent pricing and anti-censorship policies. The platform has attracted NFL teams and even El Salvador's government as clients, boasting 59 million monthly active users and a 34% year-over-year revenue growth. Its appeal lies in offering a space for "unique voices" that may be "tired of the establishment dictating what's true and what's not," seeking to diversify into various content categories beyond politics, such as music and gaming.

 

Despite its growth in users and revenue, Rumble faces financial challenges, including an adjusted EBITDA loss of $22.7 million in Q1 2025. However, its balance sheet shows no debt and significant cash reserves, suggesting a stable cash runway for more than three years based on current free cash flow. The company's valuation, at $3.02 billion, reflects investor curiosity and debate, with its anti-Big Tech narrative seen as a compelling factor in a concentrated market.

 

Vance's investment in Rumble represents a direct confluence of his political ideology and personal financial interest. By investing in a platform that explicitly caters to the "anti-Big Tech sentiment" he articulates, Vance is financially benefiting from the very grievances he campaigns on. This is not an inconsistency in terms of his stated beliefs, but rather a reinforcement of his political brand through a profitable venture. It illustrates how his investment portfolio actively supports the infrastructure of the "postliberal right" he champions, blurring the lines between political advocacy and personal profit within the burgeoning alternative media ecosystem.

 

Vance's public criticism of "Big Tech" and his call for a "de-woke-ification program" are central to his political platform. His investment in Rumble is not an inconsistency but a direct financial alignment with these stated political positions. Rumble explicitly markets itself on an anti-censorship, anti-Big Tech platform, directly appealing to the same audience and grievances that Vance articulates. This pattern indicates that Vance's financial success is directly tied to the growth and success of an alternative media ecosystem that he politically champions. This creates a symbiotic relationship where his political rhetoric helps drive users and investment to platforms like Rumble, from which he then profits. This raises questions about the integrity of political advocacy when it directly fuels personal financial gain, even if legally permissible due to exemptions for vice presidents from certain ethics requirements.

 

The Unfolding Narrative: Contradictions, Confluence, and Public Trust

The scrutiny over J.D. Vance's investment portfolio reveals a complex tapestry where his public political identity, rooted in national conservative and pro-life principles, frequently collides with or is subtly influenced by his private financial interests. The most pronounced apparent contradiction emerges in his stance on reproductive technologies. While he advocates for a national abortion ban and equates abortion to slavery, a position that logically extends to the destruction of embryos, he simultaneously expresses support for IVF, a procedure that often involves the creation and potential discarding of embryos. His vote against federal IVF protections, despite his stated support for fertility treatments, underscores a political tightrope walk, attempting to appeal to a broad "pro-family" constituency while adhering to the stricter implications of his "pro-life" ideology. This tension is further exacerbated by the real-world consequences of rulings like Alabama's, which classify embryos as children, directly impacting IVF access.

 

His investments in biotech firms like Kriya Therapeutics, AmplifyBio, and Beren Therapeutics, while not directly tied to embryonic stem cell research, operate within a broader field of advanced therapeutics that can be ethically ambiguous for a staunch pro-life advocate. AmplifyBio's admission that it does not directly use stem cell lines but does not require clients to disclose their use creates an "indirect ethical entanglement," suggesting that Vance's financial gains might, however remotely, benefit from practices that his moral framework would condemn. This highlights the intricate and often opaque nature of modern investment portfolios in rapidly evolving scientific fields.

 

The deep and enduring ties to Peter Thiel introduce another layer of complexity. Thiel's investment philosophy, driven by a vision of "life extension" and overcoming human biological limitations, hints at a transhumanist undercurrent that philosophically clashes with traditional social conservatism. While Thiel's direct "stem cell" investments are in cancer stem cells, not embryonic ones, his broader agenda of technological mastery over biology could be seen as challenging the natural order and sanctity of life that Vance publicly upholds. Vance's financial and professional proximity to Thiel suggests either a pragmatic acceptance of this broader technological trajectory or a compartmentalization of his ideological and financial pursuits.

 

Conversely, Vance's investment in Rumble represents a confluence rather than a contradiction. His financial stake in an anti-Big Tech, anti-censorship platform directly aligns with his political rhetoric and appeals to his conservative base. This symbiotic relationship between his political advocacy and personal profit illustrates a growing trend where public figures leverage their platforms to benefit financially from the very grievances they articulate, blurring the lines between political conviction and self-enrichment.

 

The analysis reveals that Vance's portfolio is not just a collection of assets but a reflection and reinforcement of his political brand. His IVF stance is a strategic ambiguity designed to appeal to a broader base while maintaining core ideological purity. The biotech investments, while not directly involving embryonic stem cells, represent an indirect ethical entanglement due to the nature of the industry and the lack of disclosure requirements from companies like AmplifyBio. This means his financial success is, at minimum, adjacent to practices he morally opposes. The Thiel connection presents a philosophical tension, where Vance's traditional conservatism meets Thiel's radical techno-optimism; Vance benefits from Thiel's network and capital, which are driven by a worldview that could be seen as antithetical to his own. Finally, the Rumble investment demonstrates a direct synergy where his anti-Big Tech rhetoric fuels the growth of a platform he profits from. The broader implication is a blurring of lines between political advocacy and personal financial gain. This challenges the traditional notion of public service, where financial interests are typically divested or strictly managed to avoid conflicts. Vance's case exemplifies how modern political figures can build wealth by investing in the very cultural and technological shifts they champion or critique, raising fundamental questions about transparency, accountability, and the integrity of public trust in an era where political identity and personal finance are increasingly intertwined.

Conclusion: A Portfolio Under Perpetual Scrutiny

J.D. Vance's investment portfolio stands as a compelling case study in the complexities of modern political finance, presenting a nuanced interplay of deeply held social convictions and strategic capitalist pursuits. His public identity as a national conservative and staunch pro-life advocate is juxtaposed against financial interests in a biotech sector that, while not directly reliant on embryonic stem cells, operates within an ecosystem where ethical lines are frequently debated. The indirect ethical entanglements within his biotech investments, coupled with the profound ideological influence of Peter Thiel's transhumanist vision, highlight the subtle yet significant tensions that exist beneath the surface of his political narrative. Conversely, his stake in Rumble demonstrates a clear, profitable synergy between his anti-Big Tech rhetoric and his personal financial gain, illustrating a growing trend where political identity and economic opportunity are inextricably linked. As Vance continues to navigate the public sphere, his portfolio will remain a subject of perpetual scrutiny, serving as a powerful reminder of the enduring importance of transparency and accountability in the intersection of power, profit, and deeply held beliefs.

 

Reference List

  1. "About Adult Stem Cell Therapy." University of Kansas Medical Center. Accessed October 26, 2024. https://www.kumc.edu/research/midwest-stem-cell-therapy-center/stem-cell-information/about-adult-stem-cell-therapy.html.

  2. "Admittedly, Vance Sounded Coherent and Slick. But Much of What He Said—Especially on Abortion, IVF and Childcare—Were Lies, Engineered for Women to Let Their Guards Down and to Distance Himself from His Extreme Views, Most of Which Are Ripped Right from Project 2025's Mandate for Leadership." Ms. Magazine. October 2, 2024. https://msmagazine.com/2024/10/02/jd-vance-abortion-ivf-lie/.

  3. "AmplifyBio Embryonic Stem Cells Research." AmplifyBio. Accessed October 26, 2024. https://www.amplify-bio.com/notice/.

  4. "AmplifyBio Embryonic Stem Cells Research." PubMed. Accessed October 26, 2024. https://pubmed.ncbi.nlm.nih.gov/19003078/.

  5. "AmplifyBio Research Areas." AmplifyBio. Accessed October 26, 2024.

https://www.amplify-bio.com/?utm_source=Newswire&utm_medium=PR&utm_campaign=Amplify_Bio_ADOC

  1. .

  2. "AmplifyBio Research Areas." Columbus Region. May 23, 2022. https://columbusregion.com/press-release/amplifybio-expands-in-the-columbus-region-investing-150-million-and-creating-263-new-jobs/.

  3. "AmplifyBio Research Areas." Newswire. Accessed October 26, 2024.

https://amplifybio.newswire.com/

  1. .

  2. "BEREN: A Bioinformatic Tool for Recovering Giant Viruses, Polinton-like Viruses, and Virophages in Metagenomic Data." bioRxiv. October 9, 2024. https://www.biorxiv.org/content/10.1101/2024.10.09.617401v1.

  3. "Beren Therapeutics Research Areas." PitchBook. Accessed October 26, 2024. https://pitchbook.com/profiles/company/470933-38.

  4. "Embryonic Stem Cell Research: The State of the Union of 'Those Who Create the Lines' and 'Those Who Draw the Lines'." Stem Cells and Development 15, no. 5 (October 2006): 623-29. https://pubmed.ncbi.nlm.nih.gov/17105397/.

  5. "J.D. Vance Has Launched a VC Fund Named After a Tolkien Artifact and Backed by Peter Thiel." Literary Hub. Accessed October 26, 2024. https://lithub.com/j-d-vance-has-launched-a-vc-fund-named-after-a-tolkien-artifact-and-backed-by-peter-thiel/.

  6. "J.D. Vance's 'Worrisome' Anti-IVF Stance: For Journalists." Northwestern University. Accessed October 26, 2024. https://news.northwestern.edu/stories/2024/july/j-d-vances-worrisome-anti-ivf-stance/?fj=1.

  7. "JD Vance Comments on Human Embryo Research." Catholic World Report. February 28, 2025. https://www.catholicworldreport.com/2025/02/28/an-open-letter-to-jd-vance-about-ivf/.

  8. "JD Vance Comments on Human Embryo Research." Mother Jones. October 2, 2024. https://www.motherjones.com/politics/2024/10/jd-vance-says-his-mamaw-had-eight-miscarriages/.

  9. "JD Vance Explicit Statement Embryonic Stem Cell Research." BioEd Online. Accessed October 26, 2024. https://www.bioedonline.org/news/nature-news-archive/stem-cell-inaction-prompts-concern/.

  10. "JD Vance Explicit Statement Embryonic Stem Cell Research." Politifact. October 12, 2022. https://www.politifact.com/article/2022/oct/12/context-what-jd-vance-said-about-rape-abortion-and/.

  11. "JD Vance Explicit Statement Embryonic Stem Cell Research." Senate Commerce Committee. September 2004. https://www.commerce.senate.gov/2004/9/embryonic-stem-cell-research-exploring-the-controversy.

  12. "JD Vance Financial Disclosures Senate." PoliticoPro. July 15, 2024. https://subscriber.politicopro.com/article/2024/07/inside-j-d-vances-health-care-investments-00168500.

  13. "JD Vance Financial Disclosures Senate." Sludge. July 10, 2025. https://readsludge.com/2025/07/10/vance-owns-investments-in-companies-receiving-defense-contracts/.

  14. "JD Vance Official Statements Embryonic Stem Cell Research." KFF.org. Accessed October 26, 2024. https://www.kff.org/womens-health-policy/issue-brief/harris-v-trump-records-and-positions-on-reproductive-health/.

  15. "JD Vance Official Statements Embryonic Stem Cell Research." The Presidency.ucsb.edu. Accessed October 26, 2024. https://www.presidency.ucsb.edu/documents/remarks-the-vice-president-the-american-dynamism-summit.

  16. "JD Vance Official Statements Embryonic Stem Cell Research." Whitehouse.gov. March 9, 2009. https://obamawhitehouse.archives.gov/the-press-office/removing-barriers-responsible-scientific-research-involving-human-stem-cells.

  17. "JD Vance Position on Human Embryonic Stem Cell Research." Biotech.law.lsu.edu. Accessed October 26, 2024. https://biotech.law.lsu.edu/research/pbc/reports/stemcell/pcbe_monitoring_stem_cell_research.pdf.

  18. "JD Vance Position on Human Embryonic Stem Cell Research." Congress.gov. Accessed October 26, 2024. https://www.congress.gov/bill/110th-congress/senate-bill/5.

  19. "JD Vance Pro-Life Stance Embryonic Stem Cells." CBMW. June 19, 2025. https://cbmw.org/2025/06/19/our-pronatalist-moment-a-christian-evaluation/.

  20. "JD Vance Pro-Life Stance Embryonic Stem Cells." MSNBC. YouTube video, 0:00. January 24, 2025.

 

  1. .

  2. "JD Vance Says His 'Mamaw' Had Eight Miscarriages. His Policies Deny Women Like Her Lifesaving Care." Mother Jones. October 2, 2024. https://www.motherjones.com/politics/2024/10/jd-vance-says-his-mamaw-had-eight-miscarriages/.

  3. "JD Vance Senate Hearings Stem Cell Research." PoliticoPro. October 26, 2020. https://subscriber.politicopro.com/article/2020/10/26/california-stem-cell-agency-faces-tougher-campaign-conditions-16-years-later-1329204/.

  4. "JD Vance Senate Votes Embryonic Stem Cell Funding." PBS. Accessed October 26, 2024. https://www.pbs.org/newshour/politics/senate-works-a-tense-overnight-session-as-republicans-seek-support-for-trumps-big-bill.

  5. "JD Vance Senate Votes Embryonic Stem Cell Funding." Vote Smart. Accessed October 26, 2024. https://justfacts.votesmart.org/candidate/key-votes/201794/jd-vance.

  6. "JD Vance Stance on Embryonic Stem Cell Research." MSNBC. YouTube video, 0:00. February 28, 2024.

 

  1. .

  2. "JD Vance Voting Record Biotechnology Ethics." CBS News. Accessed October 26, 2024. https://www.cbsnews.com/news/jd-vance-views-policy-record-2024/.

  3. "JD Vance Voting Record Biotechnology Ethics." Heritage Action. Accessed October 26, 2024. https://heritageaction.com/scorecard/members/v000137.

  4. "JD Vance Venture Capital Investments." Wikipedia. Last modified October 25, 2024. https://en.wikipedia.org/wiki/JD_Vance.

  5. "Kriya Therapeutics Embryonic Stem Cells Research." Kriya Therapeutics. Accessed October 26, 2024.

https://kriyatherapeutics.com/

  1. .

  2. "Kriya Therapeutics Embryonic Stem Cells Research." Kriya Therapeutics. Accessed October 26, 2024. https://kriyatherapeutics.com/research-development/.

  3. "Kriya Therapeutics Research Areas." FirstWord Pharma. Accessed October 26, 2024. https://firstwordpharma.com/story/5955207.

  4. "Kriya Therapeutics Technology Platform Embryonic Stem Cells." Synapse Patsnap. Accessed October 26, 2024. https://synapse.patsnap.com/article/what-are-the-primary-areas-of-focus-for-kriya-therapeutics.

  5. "Peter Thiel and the Project of a New Humanity: Immortality, Techno-States, and the Rule of the Chosen." Quasa. Accessed October 26, 2024. https://quasa.io/media/peter-thiel-and-the-project-of-a-new-humanity-immortality-techno-states-and-the-rule-of-the-chosen-they-built-a-world-for-everyone-i-m-building-one-for-those-who-survive.

  6. "Peter Thiel Controversial Investments." YouTube video, 0:00. October 26, 2024.

 

  1. .

  2. "Peter Thiel Controversial Investments." YouTube video, 0:00. October 26, 2024.

 

  1. .

  2. "Peter Thiel Investment Philosophy Biotech." Fool.com. Accessed October 26, 2024. https://www.fool.com/investing/how-to-invest/famous-investors/peter-thiel/.

  3. "Peter Thiel Investments in Controversial Biotech." ImmunoSoft. Accessed October 26, 2024. https://www.immusoft.com/wp-content/uploads/2019/01/how-peter.pdf.

  4. "Peter Thiel Investments in Embryonic Stem Cell Companies." BioPharma Dive. Accessed October 26, 2024. https://www.biopharmadive.com/news/paypal-co-founder-peter-thiel-pours-200m-into-cancer-stem-cell-biotech/405333/.

  5. "Peter Thiel Investments in Embryonic Stem Cell Companies." MacroInvent. Accessed October 26, 2024. https://macroinvent.com/4-peter-thiel-stemcentrx-moonshot-thinking/.

  6. "Peter Thiel Transhumanism Investments." Founders Fund. Accessed October 26, 2024. https://foundersfund.com/team/peter-thiel/.

  7. "Peter Thiel Transhumanism Investments." Wikipedia. Last modified October 25, 2024. https://en.wikipedia.org/wiki/Peter_Thiel.

  8. "Political Positions of JD Vance." Wikipedia. Last modified October 25, 2024. https://en.wikipedia.org/wiki/Political_positions_of_JD_Vance.

  9. "Project 2025." Wikipedia. Last modified October 25, 2024. https://en.wikipedia.org/wiki/Project_2025.

  10. "Rumble Business Model Controversies." Ainvest.com. Accessed October 26, 2024. https://www.ainvest.com/news/rumble-cloud-anti-big-tech-cloud-challenger-gaining-traction-2507/.

  11. "Rumble Business Model Controversies." YouTube video, 0:00. October 26, 2024.

 

  1. .

  2. "Rumble Financial Performance and Public Perception." Barchart. Accessed October 26, 2024. https://www.barchart.com/story/news/27418692/senator-jd-vances-portfolio.

  3. "Rumble Financial Performance and Public Perception." SEC.gov. November 13, 2023. https://www.sec.gov/Archives/edgar/data/1830081/000121390023086103/ea188136ex99-1_rumbleinc.htm.

  4. "Rumble Financial Performance and Public Perception." Simply Wall St. Accessed October 26, 2024. https://simplywall.st/stocks/us/media/nasdaq-rum/rumble/health.

  5. "Scrutiny Over Vance’s Investment Portfolio." The Independent. August 9, 2024. https://www.independent.co.uk/news/world/americas/us-politics/jd-vance-finances-donald-trump-b2594131.html.

  6. "Senator JD Vance Stands in the Way of Progress." Demand Justice. Accessed October 26, 2024. https://demandjustice.org/jd-vance-record/.

  7. "Stem Cells." Mayo Clinic. Accessed October 26, 2024. https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117.

  8. "Vance Wants a 'Pro-Family' Republicanism. His Party Isn't There Yet." Semafor. October 2, 2024. https://www.semafor.com/article/10/02/2024/vance-wants-a-pro-family-republicanism-his-party-isnt-there-yet.

  9. "Vance's Comments Calling Pregnancies from Rape and Incest 'Inconvenient' Back in Spotlight After VP Nod." The Independent. August 5, 2024. https://www.independent.co.uk/news/world/americas/us-politics/jd-vance-abortion-rape-incest-inconvenient-b2590339.html.

 

«   »

Add comment

Comments

There are no comments yet.